“We are pleased to have successfully closed this strategic acquisition and welcome the Fiagon team,“ said Keith Roberts, President and CEO of Hemostasis. „Fiagon represents a strategic technology acquisition for Hemostasis that immediately expands our portfolio of ENT technology offerings and complements our industry leading PosiSep sinus dressings, NexStat hemostats and Vectra drug delivery microsponges. Fiagon develops, and commercializes globally, innovative electromagnetic surgical navigation systems and navigable sinuplasty balloons. The combination of the Hemostasis and Fiagon portfolios will provide optimized treatment and healing technologies for sinus surgeons and patients.” Founded in 2007, Fiagon’s mission is to improve patient outcomes by equipping physicians with its proprietary, easy-to-use, accurate and integrated surgical navigation solutions. Fiagon’s Cube 4D navigation system features groundbreaking VirtuEye® one-click photoregistration. It supports both routine and complex ENT procedures enabling surgeons to track […]

Continue Reading